BR0011732A - Vacinas de dna para animais de companhia e de esporte - Google Patents

Vacinas de dna para animais de companhia e de esporte

Info

Publication number
BR0011732A
BR0011732A BR0011732-3A BR0011732A BR0011732A BR 0011732 A BR0011732 A BR 0011732A BR 0011732 A BR0011732 A BR 0011732A BR 0011732 A BR0011732 A BR 0011732A
Authority
BR
Brazil
Prior art keywords
nucleotide sequence
pets
vaccines
sport animals
antigen
Prior art date
Application number
BR0011732-3A
Other languages
English (en)
Other versions
BR0011732B1 (pt
Inventor
Laurent Jean-Charles Fischer
Simona Barzu-Le Roux
Jean-Christophe Franc Audonnet
Original Assignee
Merial Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9907604A external-priority patent/FR2794648B1/fr
Application filed by Merial Sas filed Critical Merial Sas
Publication of BR0011732A publication Critical patent/BR0011732A/pt
Publication of BR0011732B1 publication Critical patent/BR0011732B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/265—Infectious rhinotracheitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/175—Canine distemper virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/27—Equine rhinopneumonitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Patente de Invenção: "VACINAS DE DNA PARA ANIMAIS DE COMPANHIA E DE ESPORTE". A invenção refere-se a melhora da eficácia e da proteção induzida pela vacinação DNA contra os vírus da família dos Paramyxoviridae e contra os vírus herpes, nos animais de companhia e de esporte. A melhora da vacinação DNA é feita ou pela formulação da vacina com um lipídeo catiónico que contém um sal de amónio quaternário, o DMRIE, ou com modificações na seq³ência nucleotídica que codifica para o antígeno de interesse notadamente deleções do fragmento da seq³ência nucleotídica que codifica para o domínio transmembranar do antígeno de interesse, e/ou inserções de íntrons e/ou inserções de seq³ências nucleotídicas que codificam para os peptídeos sinais, ou com a adição de GM-CSF, ou com as combinações das mesmas. As vacinas assim obtidas.
BRPI0011732-3A 1999-06-10 2000-06-08 Vacinas de dna para animais de companhia e de esporte BR0011732B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR99/07604 1999-06-10
FR9907604A FR2794648B1 (fr) 1999-06-10 1999-06-10 Vaccins adn pour animaux de compagnie et de sport
US14449099P 1999-07-19 1999-07-19
US60/144,490 1999-07-19
PCT/FR2000/001592 WO2000077043A2 (fr) 1999-06-10 2000-06-08 Vaccins adn pour animaux de compagnie et de sport

Publications (2)

Publication Number Publication Date
BR0011732A true BR0011732A (pt) 2002-03-05
BR0011732B1 BR0011732B1 (pt) 2014-02-04

Family

ID=26234993

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0011732-3A BR0011732B1 (pt) 1999-06-10 2000-06-08 Vacinas de dna para animais de companhia e de esporte

Country Status (11)

Country Link
EP (1) EP1185662B1 (pt)
JP (1) JP2003502345A (pt)
KR (1) KR100768114B1 (pt)
AR (1) AR024334A1 (pt)
AU (1) AU782154C (pt)
BR (1) BR0011732B1 (pt)
CA (1) CA2375320C (pt)
CZ (1) CZ20014392A3 (pt)
NZ (1) NZ515993A (pt)
PL (1) PL210451B1 (pt)
WO (1) WO2000077043A2 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804028B1 (fr) * 2000-01-21 2004-06-04 Merial Sas Vaccins adn ameliores pour animaux de rente
FR2823222B1 (fr) 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
FR2825280B1 (fr) * 2001-06-01 2005-04-15 Merial Sas Vaccination contre le virus de l'immunodeficience feline
ES2417019T3 (es) 2003-11-13 2013-08-05 University Of Georgia Research Foundation, Inc. Procedimiento de caracterización del virus de la enfermedad de la bursitis infecciosa
DK1881845T3 (da) 2005-04-25 2010-06-07 Merial Ltd Nipah-virusvacciner
DK1954308T3 (da) * 2005-09-16 2011-10-24 Merial Ltd Stabiliseringsmidler til frysetørrede vacciner
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
JP5971945B2 (ja) 2008-04-17 2016-08-17 ピーディーエス バイオテクノロジー コーポレイションＰｄｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ カチオン性脂質の鏡像異性体による免疫応答の刺激
EP3756684A1 (en) * 2009-05-22 2020-12-30 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
US20130197612A1 (en) * 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
EP2643014A4 (en) 2010-11-24 2015-11-11 Genocea Biosciences Inc HERPES SIMPLEX TYPE 2 VIRUS VACCINES: COMPOSITIONS AND METHODS FOR STIMULATING AN IMMUNE RESPONSE
CA2885693C (en) 2011-11-23 2020-07-28 Genocea Biosciences, Inc. Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
JP6348489B2 (ja) * 2012-06-15 2018-07-04 ピーディーエス バイオテクノロジー コーポレイションＰｄｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ カチオン性脂質ワクチン組成物および使用方法
WO2014047533A1 (en) 2012-09-21 2014-03-27 Frank Bedu-Addo Improved vaccine compositions and methods of use
CN104164409A (zh) * 2014-07-18 2014-11-26 中国人民解放军军事医学科学院军事兽医研究所 含有犬gmcsf基因的重组犬瘟热病毒及其制备方法
CN104958283A (zh) * 2015-06-02 2015-10-07 北京盛大康成医疗技术有限公司 弱碱性皮肤粘膜清洗消毒组合物及其制造方法和用途
WO2017083820A1 (en) 2015-11-13 2017-05-18 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
KR101694676B1 (ko) 2015-12-10 2017-01-10 우진 비앤지 주식회사 말 선역 질병원인 국내 분리 스트렙토코커스 이콰이 균주 및 이를 포함하는 백신
US10350288B2 (en) 2016-09-28 2019-07-16 Genocea Biosciences, Inc. Methods and compositions for treating herpes
BR112021013241A2 (pt) 2019-01-04 2021-09-14 Boehringer Ingelheim Animal Health USA Inc. Cepas atenuadas de bordetella bronchiseptica, vacinas orais contendo as cepas atenuadas e métodos de preparação e uso das mesmas

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338683A (en) * 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
JPH09500013A (ja) * 1993-06-01 1997-01-07 ライフ・テクノロジーズ・インコーポレイテッド カチオン性脂質による遺伝子免疫
CA2182888C (en) * 1994-03-30 2007-08-07 Enzo Paoletti Nucleotide and amino acid sequences of canine herpesvirus gb, gc and gd and uses therefor
EP0826063A1 (en) * 1995-04-25 1998-03-04 Vical Incorporated Single-vial formulations of dna/lipid complexes
ES2109189B1 (es) * 1996-03-14 1998-05-16 Iberica Cyanamid Vectores basados en genomas virales defectivos recombinantes y su empleo en la formulacion de vacunas.
EP0954582A1 (en) * 1996-04-29 1999-11-10 Andreas Prof. Zurbriggen Polynucleotide vaccine against canine distemper
FR2751227B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
FR2751226B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
FR2751223B1 (fr) * 1996-07-19 1998-12-04 Rhone Merieux Formule de vaccin polynucleotidique felin
AU1987197A (en) * 1997-03-10 1998-09-29 Heather Lynn Davis Gene delivery to mucosal epithelium for immunization or therapeutic purpose
WO2000024428A2 (en) * 1998-10-23 2000-05-04 Heska Corporation Cationic lipid-mediated enhancement of nucleic acid immunization of cats

Also Published As

Publication number Publication date
KR20020012271A (ko) 2002-02-15
WO2000077043A3 (fr) 2001-07-19
KR100768114B1 (ko) 2007-10-17
AU782154C (en) 2006-02-09
AU782154B2 (en) 2005-07-07
CA2375320C (en) 2013-02-19
PL352212A1 (en) 2003-08-11
AR024334A1 (es) 2002-10-02
AU5540500A (en) 2001-01-02
CZ20014392A3 (cs) 2002-06-12
BR0011732B1 (pt) 2014-02-04
NZ515993A (en) 2004-04-30
JP2003502345A (ja) 2003-01-21
PL210451B1 (pl) 2012-01-31
CA2375320A1 (en) 2000-12-21
EP1185662A2 (fr) 2002-03-13
EP1185662B1 (fr) 2011-03-02
WO2000077043A2 (fr) 2000-12-21

Similar Documents

Publication Publication Date Title
BR0011732A (pt) Vacinas de dna para animais de companhia e de esporte
ES2232876T3 (es) Formula de vacuna polinucleotidica aviar.
Webster et al. Protection of ferrets against influenza challenge with a DNA vaccine to the haemagglutinin
KR100620302B1 (ko) 개 질병, 특히 호흡기 및 소화성 질병 치료용폴리뉴클레오티드 백신 제제
ES2210548T3 (es) Formula de vacuna polinucleotidica, particularmente para el tratamiento de la patologia respiratoria en los bovinos.
EP1877088B1 (en) Vaccine against pandemic strains of influenza viruses
Wallace et al. Immune responses to recombinants of the South African vaccine strain of lumpy skin disease virus generated by using thymidine kinase gene insertion
PL188409B1 (pl) Szczepionki do leczenia koni, zastosowanie plazmidu do wytwarzania szczepionki i zestaw do szczepienia koni
RU2016145597A (ru) Вакцины на основе нуклеиновых кислот
KR20000065257A (ko) 고양이과 폴리뉴클레오티드 백신 제제
CN108026515B (zh) 用于预防和/或治疗感染性疾病以及用于治疗肿瘤疾病的减毒流感病毒载体
BR9712970A (pt) Método para produção de vacina para proteção contra virus sincitial respiratório, mistura de proteìna de fusão purificada, composição imunogênica
ES2711878T3 (es) Vacuna contra el virus del herpes equino 1 recombinante que contiene glicoproteína C mutada y usos de la misma
YU99102A (sh) Postupci i kompozicija za oralnu vakcinaciju
Cubillos et al. Inclusion of a specific T cell epitope increases the protection conferred against foot-and-mouth disease virus in pigs by a linear peptide containing an immunodominant B cell site
ES2636958T3 (es) Vacuna mejorada contra calicivirus felino
Almeida et al. Indirect oral immunization of captive vampires, Desmodus rotundus
Zhang et al. Fusion to chicken C3d enhances the immunogenicity of the M2 protein of avian influenza virus
TW200505475A (en) Avian E. coli vaccine for protection against colibacillosis
RU2660566C2 (ru) Иммунизация вектором на основе вируса бешенства, экспрессирующим чужеродный белковый антиген
Jackson et al. Spontaneous recovery from the encephalomyelitis in mice caused by street rabies virus
Boyle et al. Influence of dose and route of inoculation on responses of chickens to recombinant fowlpox virus vaccines
WO2013011184A2 (es) Molécula quimerica util en inmunoterapia frente a la leishmaniosis, que comprende un fragmento de la proteina pfr1 de leishmania infantum con epitopes especificos inmunodominantes
Huang et al. Efficiency of live attenuated and inactivated rabies viruses in prophylactic and post exposure vaccination against the street virus strain
CA2407036A1 (en) A nucleic acid construct encoding a processing component derived from the n-terminal region of the hepatitis virus orf2, and an antigenic polypeptide

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/02/2014, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 22A ANUIDADE.

B24D Patent annual fee: restoration after fee payment
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 23A ANUIDADE.